The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Open accessAbstract
BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease. METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months. RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49). CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citation(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Self-citationBhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
One-year cardiovascular event rates in outpatients with atherothrombosis
Steg, P. G., Bhatt, D. L., Wilson, P. W. F., D’Agostino, R., Ohman, E. M., Röther, J., Liau, C.-S., Hirsch, A. T., Mas, J.-L., Ikeda, Y., et al. (2007) · JAMA · doi:10.1001/jama.297.11.1197 · Cited by 1,382
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, P., Fox, K. A. A., Lipka, L., Liu, X., Nicolau, J. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200933 · Cited by 966
Fowkes, F. G. R. (2010) · JAMA · doi:10.1001/jama.2010.221 · Cited by 624
Self-citationBonaca, M. P., Bhatt, D. L., Storey, R. F., Steg, P. G., Cohen, M. C., Kuder, J., Goodrich, E. L., Nicolau, J. C., Parkhomenko, A. N., Lopez-Sendon, J. L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.524 · Cited by 385
Self-citation
Cited by
Sorted by citations
Items 101–200 of 633
Weissler, E. H., Jones, W. S., Désormais, I., Debus, S., Mazzolai, L., Espinola–Klein, C., Nikol, S., Nehler, M. R., Sillesen, H. H., Aboyans, V., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.001 · Cited by 35
Self-citationCause of Death Among Patients With Peripheral Artery Disease
Kochar, A., Mulder, H. S., Rockhold, F. W., Baumgärtner, I., Berger, J. S., Blomster, J., Fowkes, F. G. R., Katona, B. G., Lópes, R. D., Al‐Khalidi, H. R., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006550 · Cited by 37
Self-citation2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial
Norgren, L., Patel, M. R., Hiatt, W. R., WOJDYLA, D. M., Fowkes, F. G. R., Baumgärtner, I., Mahaffey, K. W., Berger, J. S., Jones, W. S., Katona, B. G., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.11.006 · Cited by 34
Self-citationKraaijpoel, N., Tritschler, T., Guillo, E., Girard, P., & Gal, G. L. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14570 · Cited by 33
A review of the effects of ticagrelor on adenosine concentration and its clinical significance
Akkaif, M. A., Ng, M. L., Kader, M. A. S. A., Daud, N. A. A., Sha’aban, A., & Ibrahim, B. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00309-0 · Cited by 33
Willems, L. H., Maas, D. P. M. S. M., Kramers, K., Reijnen, M. M. P. J., Riksen, N. P., Cate, H. T., van der Vijver-Coppen, R. J., de Borst, G. J., Mees, B., Zeebregts, C. J., et al. (2022) · Drugs · doi:10.1007/s40265-022-01756-6 · Cited by 37
Field‐Effect Transistor‐Based Biosensor for pH Sensing and Mapping
Ren, H., Liang, K., Li, D., Chen, Y., Tang, Y., Wang, Y., Li, F., Liu, G., & Zhu, B. (2023) · Advanced Sensor Research · doi:10.1002/adsr.202200098 · Cited by 32
Danielak, D., Karaźniewicz‐Łada, M., & Główka, F. K. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1421634 · Cited by 32
Weitz, J. I., Angiolillo, D. J., Geisler, T., & Heitmeier, S. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713376 · Cited by 33
Multi‐vital on‐skin optoelectronic biosensor for assessing regional tissue hemodynamics
Xin, M., Yu, T., Jiang, Y., Tao, R., Li, J., Ran, F., Zhu, T., Huang, J., Zhang, J., Zhang, J., et al. (2022) · SmartMat · doi:10.1002/smm2.1157 · Cited by 31
Guo, C., Chen, L., Chan, E. W., Cheung, K. S., Isshiki, T., Wong, I. C. K., & Leung, W. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15059 · Cited by 34
Hopley, C. W., Kavanagh, S. T., Patel, M. R., Ostrom, C., Baumgärtner, I., Berger, J. S., Blomster, J., Fowkes, F. G. R., Jones, W. S., Katona, B. G., et al. (2019) · Vascular Medicine · doi:10.1177/1358863x19864172 · Cited by 32
Self-citationFudim, M., Hopley, C. W., Huang, Z., Kavanagh, S. T., Rockhold, F. W., Baumgärtner, I., Berger, J. S., Blomster, J., Fowkes, F. G. R., Katona, B. G., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006512 · Cited by 34
Self-citationExercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease
Biswas, M., Capell, W. H., McDermott, M. M., Jacobs, D. L., Beckman, J. A., Bonaca, M. P., & Hiatt, W. R. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.08.012 · Cited by 31
Self-citationAssociation of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events
Guédon, A. F., de Fréminville, J.-B., Mirault, T., Mohamedi, N., Rance, B., Fournier, N., Paul, J., Messas, E., & Goudot, G. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45720 · Cited by 32
Poor attainment of lipid targets in patients with symptomatic peripheral artery disease
Dopheide, J. F., Papac, L., Schindewolf, M., Baumgärtner, I., & Drexel, H. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.013 · Cited by 29
Samsky, M. D., Hellkamp, A. S., Hiatt, W. R., Fowkes, F. G. R., Baumgärtner, I., Berger, J. S., Katona, B. G., Mahaffey, K. W., Norgren, L., Blomster, J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018684 · Cited by 30
Self-citationRymer, J. A., Narcisse, D. I., Cosiano, M., Tanaka, J., McDermott, M. M., Treat‐Jacobson, D., Conte, M. S., Tuttle, B., Patel, M. R., & Smolderen, K. G. E. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011320 · Cited by 32
Self-citationConte, M. S., Aulivola, B., Barshes, N. R., Bertges, D. J., Corriere, M. A., Murad, M. H., Powell, R. J., Reed, A. B., Robinson, W. P., & Simons, J. P. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.04.041 · Cited by 33
Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies
King, R. W., Canonico, M. E., Bonaca, M. P., & Hess, C. N. (2022) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2022.100513 · Cited by 35
Medical management of claudication
Ratchford, E. V. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.02.040 · Cited by 31
Peripheral interventions and antiplatelet therapy: Role in current practice
Singh, P. P., Harper, Y., Oliphant, C. S., Morsy, M., Skelton, M., Askari, R., & Khouzam, R. N. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i7.583 · Cited by 28
Fox, K. A. A., Eikelboom, J. W., Anand, S. S., Bhatt, D. L., Bosch, J., Connolly, S. J., Harrington, R. A., Steg, P. G., & Yusuf, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy347 · Cited by 28
Fanaroff, A. C., Clare, R. M., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., Alexander, J. H., Jones, W. S., Harrison, R. W., Mehta, R. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037202 · Cited by 26
Self-citationPiechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., & Kabłak-Ziembicka, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051508 · Cited by 29
Carlo, M. D., Minno, G. D., Sayre, T., Fazeli, M. S., Siliman, G., & Cimminiello, C. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200820141131 · Cited by 27
Cong, G., Cui, X. D., Ferrari, R., Pipinos, I. I., Casale, G. P., Chattopadhyay, A., & Sachdev, U. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123974 · Cited by 27
Moon, J. Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417708617 · Cited by 27
Mackman, N., Spronk, H. M. H., Stouffer, G. A., & Cate, H. T. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310048 · Cited by 29
Jansen, S. J., de Borst, G. J., Hinchliffe, R. J., & Teraa, M. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.09.021 · Cited by 28
Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications
Goli, R. R., Contractor, M. M., Nathan, A. S., Tuteja, S., Kobayashi, T., & Giri, J. S. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0698-2 · Cited by 25
Meyer, B. M., Campos, J. K., de Beaufort, J. C. C., Chen, I., Khan, M., Amin, G., Zarrin, D., Lien, B. V., & Coon, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11082234 · Cited by 25
Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease
Hess, C. N., Daffron, A., Nehler, M. R., Morrison, J. T., Buchanan, C. E., Szarek, M. J., Anderson, V. E., Cannon, C. P., Hsia, J. A., Saseen, J. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.04.034 · Cited by 25
Antithrombotic Strategies for Patients With Peripheral Artery Disease
Bonaca, M. P., Barnes, G. D., Bauersachs, R. M., Bessada, Y., Conte, M. S., Dua, A., Hess, C. N., Serhal, M., Mena‐Hurtado, C., Weitz, J. I., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.027 · Cited by 24
Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease
Hess, C. N., & Bonaca, M. P. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.120.009584 · Cited by 25
Fox, K. A. A., Anand, S. S., Aboyans, V., Cowie, M., Debus, E. S., Zeymer, U., Monje, D., Vogtländer, K., Lawatscheck, R., & Gay, A. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.01.015 · Cited by 24
Sex and Racial Disparities in Peripheral Artery Disease
Divakaran, S., Krawisz, A. K., Secemsky, E. A., & Kant, S. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319399 · Cited by 27
Johnston, A., Vemulapalli, S., Gosch, K., Aronow, H., Abbott, D., Patel, M., Smolderen, K., Shishebor, M., Spertus, J., & Jones, S. W. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.07.039 · Cited by 18
Self-citationZhang, N., Xu, W., Li, O., & Zhang, B. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01419-y · Cited by 24
Talasaz, A. H., Sadeghipour, P., Ortega‐Paz, L., Kakavand, H., Aghakouchakzadeh, M., Beavers, C. J., Fanikos, J. R., Eikelboom, J. W., Siegal, D. M., Monréal, M., et al. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01003-3 · Cited by 22
Ticagrelor resistance: a case series and algorithm for management of non-responders
Laurent, D., Dodd, W., Small, C. N., Gooch, M. R., Ghosh, R., Goutnik, M., Blatt, T., Porche, K. M., Geh, N., Adamczak, S. E., et al. (2021) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2021-017638 · Cited by 22
Galli, M., Franchi, F., Rollini, F., Been, L. F., Jaoude, P. A., Rivas, A., Zhou, X., Jia, S., Maaliki, N., Lee, C. H., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1730-8725 · Cited by 22
Zhu, Y., Jung, J., Anilkumar, S., Ethiraj, S., Madira, S., Tran, N. A., Mullis, D. M., Casey, K. M., Walsh, S. K., Stark, C. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-14085-1 · Cited by 22
McClure, G. R., Kaplovitch, E., Narula, S., Bhagirath, V. C., & Anand, S. S. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1198-5 · Cited by 23
Tardalkar, K. R., Marsale, T. B., Bhamare, N. C., Kshersagar, J. R., Chaudhari, L. R., & Joshi, M. G. (2022) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-021-00411-7 · Cited by 23
Gwyn, J. C., Thomas, M. R., & Kirchhof, P. F. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx002 · Cited by 21
Antithrombotic Therapy in Peripheral Artery Disease
Jones, W. S., & Patel, M. R. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.021 · Cited by 22
Self-citationLee, H., See, L., Li, P., Liu, J., Chao, T., Chang, S., Wu, L., Yeh, Y., Kuo, C.-T., Chan, Y., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz072 · Cited by 21
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 24
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
Angiolillo, D. J., Cao, D., Sartori, S., Baber, U., Dangas, G., Zhang, Z., Vogel, B., Kunadian, V., Briguori, C., Cohen, D. J., et al. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.08.019 · Cited by 21
Peripheral artery disease and antiplatelet treatment
Tsigkou, V., Siasos, G., Rovos, K., Tripyla, N., & Tousoulis, D. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.011 · Cited by 25
Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine
Minno, G. D., & Tremoli, E. (2017) · Haematologica · doi:10.3324/haematol.2016.156000 · Cited by 21
Bálint, A., Tornyos, D., Abdallaoui, O. E. A. E., Kupó, P., & Komócsi, A. (2021) · Stroke · doi:10.1161/strokeaha.120.032670 · Cited by 21
Malhotra, K., Goyal, N., Kasunich, A. S., Sheth, S. A., Katsanos, A. H., Alexandrov, A. V., & Tsivgoulis, G. K. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.05.001 · Cited by 20
Bae, J. S., Ahn, J., Jang, J. Y., Cho, S. Y., Kang, M. G., Kim, K., Park, H. W., Koh, J., Park, Y., Hwang, S., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02103-w · Cited by 20
Ghamraoui, A. K., & Ricotta, J. J. (2020) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2020.04.518 · Cited by 20
Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Galli, M., ten Berg, J. M., Valgimigli, M., Capodanno, D., Gragnano, F., Kimura, T., Bhatt, D. L., Gibson, C. M., Mehran, R., & Angiolillo, D. J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf718 · Cited by 24
Ticagrelor therapy and atrioventricular block: Do we need to worry?
Maria, E. D., Borghi, A., Modonesi, L., & Cappelli, S. (2017) · World Journal of Clinical Cases · doi:10.12998/wjcc.v5.i5.178 · Cited by 19
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor
Triska, J., Maitra, N. S., Deshotels, M. R., Haddadin, F. I., Angiolillo, D. J., Vilahur, G., Jneid, H. M., Atar, D., & Birnbaum, Y. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07373-5 · Cited by 19
A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice
Arockiam, S., Staniforth, B., Kepreotis, S., Maznyczka, A., & Bulluck, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311132 · Cited by 21
Review of the Ticagrelor Trials Evidence Base
Herron, G. C., & Bates, E. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031606 · Cited by 21
Halle, T. R., Benarroch‐Gampel, J., Teodorescu, V. J., & Rajani, R. R. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.06.152 · Cited by 19
Nelson, T. A., Parker, W. A., Lakic, T. G., Westerbergh, J., James, S. K., Siegbahn, A. G., Becker, R. C., Himmelmänn, A., Wallentin, L. C., & Storey, R. F. (2021) · Platelets · doi:10.1080/09537104.2021.1934667 · Cited by 19
Narcisse, D. I., Ford, C. B., Weissler, E. H., Lippmann, S., Smerek, M., Greiner, M. A., Hardy, N. C., O’Brien, B., Sullivan, R., Brock, A. J., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.05.014 · Cited by 19
Self-citationChazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Russo, C. D., Frater, I., Kuruvilla, R., Lip, S. Z. L., O'Neill, H., Burke, K. A., Chaplin, V., Doney, A. S. F., Elyas, S., Greaves, N. S., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70370 · Cited by 21
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial
Govsyeyev, N., Nehler, M. R., Wang, C. C. L., Kavanagh, S. T., Hiatt, W. R., Long, C. A., Jones, W. S., Fowkes, F. G. R., Berger, J. S., Baumgärtner, I., et al. (2021) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2021.08.096 · Cited by 18
Self-citationKranendonk, J., Willems, L. H., van der Vijver-Coppen, R. J., Coenen, M. J. H., Adang, E., Donders, R., Zeebregts, C. J., Deneer, V. H. M., Reijnen, M. M. P. J., Kramers, C., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.08.001 · Cited by 18
Kastora, S. L., Eley, J., Gannon, M., Melvin, R., Munro, E. N., & Makris, S. A. (2022) · Journal of Vascular Research · doi:10.1159/000527079 · Cited by 18
Galli, M., Franchi, F., Rollini, F., Ortega‐Paz, L., D’Amario, D., Caterina, R. D., Mehran, R., Gibson, C. M., & Angiolillo, D. J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2154651 · Cited by 19
Racial and Socioeconomic Health Disparities in Peripheral Artery Disease
Thomas, V. E., & Beckman, J. A. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031446 · Cited by 21
How To Assess a Claudication and When To Intervene
Hossain, P., Kokkinidis, D. G., & Armstrong, E. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1227-4 · Cited by 18
Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis
Olie, R. H., van der Meijden, P. E. J., Spronk, H. M. H., & Cate, H. T. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_357 · Cited by 20
Navarese, E. P., Wernly, B., Lichtenauer, M., Petrescu, A. M., Kołodziejczak, M. M., Lauten, A., Frediani, L., Veulemanns, V., Wańha, W., Wojakowski, W., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.07.009 · Cited by 18
Oral antiplatelet agents in cardiovascular disease
Pultar, J., Wadowski, P. P., Panzer, S., & Gremmel, T. (2018) · VASA · doi:10.1024/0301-1526/a000753 · Cited by 18
Lüscher, T. F., Davies, A., Beer, J. H., Valgimigli, M., Nienaber, C. A., Camm, A. J., Baumgärtner, I., Diener, H., & Konstantinides, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab642 · Cited by 18
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions
Canonico, M. E., Piccolo, R., Avvedimento, M., Leone, A., Esposito, S., Franzone, A., Giugliano, G., Gargiulo, G., Hess, C. N., Berkowitz, S. D., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10040164 · Cited by 18
Halim, H., Pinkaew, D., Chunhacha, P., Sinthujaroen, P., Thiagarajan, P., & Fujise, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218934 · Cited by 17
Muzurović, E. M., & Mikhailidis, D. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420941675 · Cited by 17
Ye, Y., Nylander, S., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6763-9 · Cited by 17
Busch, L., Stern, M. E., Dannenberg, L., Mourikis, P., Gröne, M., Özaslan, G., Heinen, Y., Heiß, C., Sansone, R., Polzin, A., et al. (2020) · Platelets · doi:10.1080/09537104.2020.1742314 · Cited by 17
The Treatment Gap in Peripheral Artery Disease
Hiatt, W. R., & Rogers, R. K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.024 · Cited by 17
Self-citationRole of rivaroxaban in the prevention of atherosclerotic events
Sanmartı́n, M., Bellmunt-Montoya, S., Cosı́n-Sales, J., García–Moll, X., Riera‐Mestre, A., Almendro‐Delia, M., Hernández, J. L., Lozano, F., Mazón, P., & Fernández, C. S. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1637732 · Cited by 16
Balletshofer, B. M., Ito, W. D., Lawall, H., Malyar, N. M., Oberländer, Y., Reimer, P., Rittig, K., & Zähringer, M. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9250 · Cited by 18
Gupta, R., Kirtane, A. J., Ozan, M. O., Witzenbichler, B., Rinaldi, M. J., Metzger, D. C., Weisz, G., Stuckey, T., Brodie, B. R., Mehran, R., et al. (2017) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004904 · Cited by 16
Antithrombotics in stable peripheral artery disease
Kaplovitch, E., Rannelli, L., & Anand, S. S. (2019) · Vascular Medicine · doi:10.1177/1358863x18820123 · Cited by 19
Li, Y., Chen, J., Lin, T., Wang, Y.-C., Wu, C., Yeh, H., Huang, C., Chang, K., Wu, C., Chen, P., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.04.007 · Cited by 17
Wan, D., Dehghan, M., de Souza, R. J., Ramasundarahettige, C. F., Eikelboom, J. W., Bosch, J., Maggioni, A. P., Bhatt, D. L., Yusuf, S., & Anand, S. S. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad062 · Cited by 16
Bierowski, M. J., Galanis, T., Majeed, A., & Mofid, A. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2023.05.007 · Cited by 16
Landi, A., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Fox, K. A. A., Halvorsen, S., James, S. K., Jüni, P., Leonardi, S., et al. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad158 · Cited by 15
Antithrombotic Therapy in High Bleeding Risk, Part II
Galli, M., Gragnano, F., Berteotti, M., Marcucci, R., Gargiulo, G., Calabrò, P., Terracciano, F., Andreotti, F., Patti, G., Caterina, R. D., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.09.011 · Cited by 16
A comprehensive review on antithrombotic therapy for peripheral artery disease
Gupta, R., Majumdar, M., Imran, R., & Yi, J. A. (2022) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2022.04.004 · Cited by 15
Kieback, A. G., Espinola–Klein, C., Lamina, C., Moebus, S., Tiller, D., Lorbeer, R., Schulz, A., Meisinger, C., Medenwald, D., Erbel, R. M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224608 · Cited by 16
Li, H., Feng, Q., Tsoi, M. F., Fei, Y., & Cheung, B. M. Y. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa065 · Cited by 14
Biscetti, F., Cecchini, A. L., Rando, M. M., Nardella, E., Gasbarrini, A., Massetti, M., & Flex, A. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.10.003 · Cited by 14
Yeh, C., Chou, Y.-J., Tsai, T.-H., Hsu, P. W.-C., Li, C., Chan, Y.-H., Tsai, S., Ng, S., Chou, K.-M., Lin, Y., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010116 · Cited by 14
Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review
Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K. M., Vogel, B., & Mehran, R. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s391400 · Cited by 17
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment
Tannu, M., Hess, C. N., Gutierrez, J. A., Lópes, R. D., Swaminathan, R. V., Altin, S. E., & Rao, S. V. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02063-0 · Cited by 15
Is ticagrelor worth its high cost and side-effects?
Guerbaaï, R.-A., Mahata, I., Maréchaux, S., Jemtel, T. H. L., & Ennezat, P. (2018) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2018.1469371 · Cited by 15
Metadata
- Authors
- Hiatt, W. R., Fowkes, F. G. R., Heizer, G., Berger, J. S., Baumgartner, I., Held, P., Katona, B. G., Mahaffey, K. W., Norgren, L., Jones, W. S., Blomster, J., Millegård, M., Reist, C., & Patel, M. R.
- Affiliations
- University of Bern (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-01-05
- Volume
- 376
- Issue
- 1
- Pages
- 32-40
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2556414715
- Cited by
- 636
- References
- 14
- Citations by year
- 2026: 26 · 2025: 42 · 2024: 57 · 2023: 59 · 2022: 60 · 2021: 85 · 2020: 75 · 2019: 80 · 2018: 87 · 2017: 60
- FWCI
- 63.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Purdue University
- Boston Scientific Corporation
- Cook Medical
- Purdue Pharma
- MyoKardia
- Mitsubishi Tanabe Pharma Corporation
- St. Jude Medical
- Abbott Vascular
- Janssen Research and Development
- Duke Clinical Research Institute
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, peripheral arterial disease, antiplatelet therapy, major bleeding, acute limb ischemia, cardiovascular events, ankle-brachial index, critical limb ischemia, claudication, lower extremity revascularization, cardiovascular mortality, ischemic stroke, myocardial infarction, P2Y12 inhibitors, aspirin, atherosclerosis
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Hemorrhage, Humans, Intermittent Claudication, Ischemia, Leg, Male, Middle Aged, Platelet Aggregation Inhibitors, Ticlopidine, Kaplan-Meier Estimate, Peripheral Arterial Disease, Purinergic P2Y Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
